MRSN vs. MCRB, OKYO, SPRO, TARA, IOBT, GNLX, AVTX, IMRX, CNTB, and LIMN
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Seres Therapeutics (MCRB), OKYO Pharma (OKYO), Spero Therapeutics (SPRO), Protara Therapeutics (TARA), IO Biotech (IOBT), Genelux (GNLX), Avalo Therapeutics (AVTX), Immuneering (IMRX), Connect Biopharma (CNTB), and Liminatus Pharma (LIMN). These companies are all part of the "pharmaceutical products" industry.
Mersana Therapeutics vs. Its Competitors
Mersana Therapeutics (NASDAQ:MRSN) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
Mersana Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.9, indicating that its share price is 190% more volatile than the S&P 500.
Seres Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%. Seres Therapeutics' return on equity of -350.16% beat Mersana Therapeutics' return on equity.
Seres Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Mersana Therapeutics had 11 more articles in the media than Seres Therapeutics. MarketBeat recorded 12 mentions for Mersana Therapeutics and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.84 beat Mersana Therapeutics' score of 0.14 indicating that Seres Therapeutics is being referred to more favorably in the news media.
Mersana Therapeutics currently has a consensus price target of $56.60, indicating a potential upside of 629.38%. Seres Therapeutics has a consensus price target of $73.67, indicating a potential upside of 280.53%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Mersana Therapeutics is more favorable than Seres Therapeutics.
Summary
Mersana Therapeutics beats Seres Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MRSN) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access